Teladoc Q3 revenue down 2% to $626.4M; net loss widens to $49.5M; adj. EBITDA falls 16%

Teladoc Health, Inc.

2025-Q3 EPS reported -$1.00 revenue$1,887,708,000

Revenue $626.4M (-2% YoY); net loss $49.5M ($0.28 per share) vs. $33.3M loss a year ago.
Adjusted EBITDA $69.9M (-16% YoY); Integrated Care segment rev +2% to $389.5M; BetterHelp rev -8% to $236.9M.
Full-year 2025 guidance: revenue $2.51B-$2.539B; adj. EBITDA $270M-$287M; net loss per share ($1.25)-($1.10).
Cash from ops $99.3M in Q3; free cash flow $67.9M vs. $79.0M a year ago.
Non-cash goodwill impairment of $12.6M in Q3; $17.0M stock-based comp; $85.8M amortization intangibles.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.